证券代码：002105 证券简称：信隆健康 公告编号：2024-017 深圳信隆健康产业发展股份有限公司 2023年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示 1.公司董事会于2024年4月24日在《证券时报》以及巨潮资讯网刊登了《关于召开2023 年年度股东大会的通知》； 2.本次股东大会以现场投票和网络投票表决相结合的方式召开； 3.本次股东大会召开期间无增加、否决或变更提案的情况； 4.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议的召开情况 1、深圳信隆健康产业发展股份有限公司（以下简称：公司）召开2023年年度股东大会于 2024年4月24日以公告的方式发出会议通知，《关于召开2023年年度股东大会的通知》于2024 年4月24日刊登于《证券时报》和巨潮资讯网（www.cninfo.com.cn ）。 （1）会议现场召开时间：2024年5月21日下午14:00 网络投票时间：2024年5月21日。其中，通过深圳证券交易所互联网投票系统投票的具体 时间为：2024年5月21日上午9:15至2024年5月21 ...

康达律师事务所 股东大会法律意见书 深圳市福田区中心四路一号嘉里建设广场 T1-19 层 19/F, Kerry Plaza Tower 1,1-1 Zhongxin4th Road, Futian District, Shenzhen 邮编/Zip Code:518048 电话/Tel:0755-88600388 电子邮箱/E-mail：kangda@kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达（深圳）律师事务所 关于深圳信隆健康产业发展股份有限公司 2023年年度股东大会的 法律意见书 康达股会字【2024】第 1938 号 致：深圳信隆健康产业发展股份有限公司（下称"公司"） 北京市康达（深圳）律师事务所（以下简称"本所"）接受公司的委托，指 派本所律师参加公司 2023 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下 ...

重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 深圳信隆健康产业发展股份有限公司 2024 年第一季度报告 证券代码：002105 证券简称：信隆健康 公告编号：2024-015 深圳信隆健康产业发展股份有限公司 2024 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减（%） | | 营业收入（元） | 240,067,340.31 | 271,574,492.33 | -11.60% | | 归属于上市公司股东的净利润（元） | 2,457,102 ...

深圳信隆健康产业发展股份有限公司 2023 年度独立董事述职报告 （甘勇明） 公司股东： 本人作为深圳信隆健康产业发展股份有限公司（以下简称"公司"）董事会 独立董事，根据《公司法》《证券法》和证监会《上市公司独立董事管理办法》 第三十三条的规定，以及《公司章程》《独立董事工作制度》等规定，本着独立、 客观、审慎的原则，忠实、勤勉、尽职地履行职责，积极发挥独立董事作用，切 实履行了独立董事的责任与义务。在 2023 年的工作中，本人积极出席相关会议， 认真参加公司董事会、股东大会，审慎审议董事会和董事会专门委员会的各项提 案，对公司重大事项发表了独立意见，发挥了独立董事的独立性和专业性作用， 维护了公司及股东尤其是中小股东的权益。现将本人 2023 年度工作情况作简要 汇报。 一、全年出席董事会方式、次数及投票情况，列席股东大会次数 2023 年度，公司召开了 8 次董事会会议，4 次股东大会。本人实际参加董 事会 8 次，列席 4 次股东大会。本人在开会前收到了相关会议文件，了解了相关 情况，会上认真审议每个议案，为公司决策起到积极作用。 召开独立董事专门会议。2024年，独立董事将根据工作制度履行独立董事 ...

深圳信隆健康产业发展股份有限公司 独立董事王巍望 2023 年度述职报告 公司股东: 作为深圳信隆健康产业发展股份有限公司（以下简称"公司"） 的独立董事，我严格按照《公司法》、《关于在上市公司建立独立 董事的指导意见》、《关于加强社会公众股股东权益保护的若干规 定》、《独立董事工作制度》及《公司章程》等相关法律法规和规 章制度的规定和要求，认真履行独立董事职责，谨慎、认真、勤 勉地行使公司所赋予独立董事的权利，充分发挥独立董事的作用， 维护了公司及股东特别是中小股东的权益。现将 2023 年度我履 行独立董事职责的工作情况汇报如下： 第一部分：独立董事的基本情况 王巍望出生于 1980 年 02 月，中国国籍，大专学历，金融专 业。该独立董事由公司董事会提名委员会提名，经公司 2018 年、 2021 年度股东大会一致通过，任期自 2019 年 5 月到 2025 年 5 月。 王巍望女士最近五年的工作经历为：2014 年 1 月至 2019 年 1 月任职深圳工业总会副秘书长，2019 年 1 月至 2021 年 11 月任职 深圳工业总会常务副秘书长，2021 年 11 月至今任职深圳工业总 会秘书长， ...

深圳信隆健康产业发展股份有限公司 2023年度内部控制评价报告 深圳信隆健康产业发展股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监 管要求（以下简称企业内部控制规范体系）,结合本公司（以下简称公司） 内部控制制度和评价办法,在内部控制日常监督和专项监督的基础上,我们 对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行 了评价。 一、重要声明 按照企业内部控制规范体系的规定,建立健全和有效实施内部控制,评 价其有效性,并如实披露内部控制评价报告是公司董事会的责任。监事会对 董事会建立和实施内部控制进行监督。经理层负责组织领导企业内部控制的 日常运行（如附表一）。公司董事会、监事会及董事、监事、高级管理人员 保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏,并对报告内 容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报 告及相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内 部控制存在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由 于情况的变化可能导致内部控制 ...

关于深圳信隆健康产业发展股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A. UDC Times Building No 8 Xinye Road Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn _ " " " " " e 目 录 | | 页 次 | | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 审核说明 | 1-2 | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | 3 | 二、注册会计师的责任 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-8887999 ...

U.S. Bicycle Market Trends - The U.S. bicycle market faces high inventory levels in 2023 due to explosive consumption during 2020-2022, with sales weakened by interest rate hikes and high inflation. Brands are offering 30%-40% discounts to clear inventory, putting pressure on small and medium brands[30] - U.S. e-bike sales surpassed 1 million units in 2023, growing 25% YoY. The North American e-bike market is projected to reach $4.1 billion by 2028[36] European E-bike Market Trends - The European e-bike market is projected to reach 12 million units by 2030, with a shift towards leisure, short-distance commuting, and intelligent transportation. Traditional bicycle demand is declining sharply[31] - European e-bike market inventory remains high, with 30%-40% discounts offered. The UK reduced anti-dumping duties on Chinese e-bikes from 62.1% to 16.2%, with a total tax rate of 33.4%[37] Global E-bike Market Growth - The global e-bike market is expected to grow from $28.9 billion in 2023 to $52.6 billion by 2028, with a 12% CAGR. The e-cargo bike market reached $2.04 billion in 2023[35] Company Market Position and Competitors - The company holds 25% of the global bicycle control parts market and 15% of the suspension fork market, with main competitors being Suntour (70%) and RST (10%)[39] - Competitor SR has expanded production capacity in Germany and Taiwan, with 6 service centers in Germany, strengthening its local presence[41] Shared Mobility Challenges - The U.S. shared e-scooter market faces challenges, with Bird Global filing for bankruptcy in December 2023[42] - European e-scooter shipments declined 50%-70% in 2023, with Xiaomi reducing its annual budget by over 90%, cutting approximately 900,000 units[44] Shipping and Logistics - Red Sea shipping crisis caused container shipping rates to surge by nearly 600%, with rates for a 40-foot container exceeding $10,000[49] - Shanghai to US West Coast shipping rates rose 43.2% to $3,974/FEU, while Shanghai to US East Coast rates increased 47.9% to $5,813/FEU[50] - New FAK rates effective January 15 set 40-foot container rates at $5,000 for US West Coast and $7,000 for East Coast/Gulf ports[51] Shared Mobility Mergers and Market Leaders - Tier Mobility and Dott merger expected to create Europe's largest shared mobility operator with combined revenue exceeding €200 million[52][54] - Ninebot maintains China's top position in smart two-wheeled electric vehicles with leading sales in 4000+/5000+ RMB premium segments[56] - Ninebot's global electric scooter production surpassed 10 million units, with 2.3 million units sold in 2020, accounting for 85% of China's total production[59] Global Electric Scooter Market Forecast - QY Research forecasts global electric scooter production to reach 10.01 million units by 2027, with a market value of $3.34 billion[59] - Boston Consulting Group predicts global smart electric scooter market could reach $50 billion by 2025, with $15 billion in Europe/US and $8 billion in China[59] Micromobility Trends in Australia - Australia's micromobility market grew fivefold since 2017, with over 250,000 personal electric scooters in use[60] - 97% of Australian users find electric scooters more enjoyable than e-bikes, with 85% using them for leisure and 30% planning to increase usage[60] Electric Scooter Market in Russia - Electric scooter sales in Russia increased by 43% year-on-year, reaching 245,000 units in Q1 2023[62] - 85% of personal mobility vehicle purchases in Russia are electric scooters, with 10% being electric bicycles[62] - Shared electric scooter users in Russia aged 50+ increased by 84% over the past year[63] Elderly and Disabled Assistive Devices Market - The global elderly and disabled assistive devices market is projected to reach 299.31 billion yuan by 2030, with a CAGR of 9.11% from 2023[69] - North America holds the largest share of the global wheelchair market at 32.47% in 2023[69] - The Asia-Pacific region is the fastest-growing wheelchair market, expected to grow at a CAGR of 11.8% from 2023 to 2028[73] Rehabilitation Medical Device Market in China - China's rehabilitation medical device market is projected to reach 67 billion yuan by 2023, growing at a CAGR of 19.1%[74] - Global electric wheelchair retail sales are expected to reach 322.023 billion yuan in 2023, a 48.3% increase from 2022[75] - Smart electric wheelchair production is expected to reach 183.021 billion yuan in 2023, a 58.4% increase from 2022[75] - China's electric wheelchair production reached approximately 2.56 million units in 2022[75] Financial Performance and Revenue Decline - Total operating revenue decreased by 47.18% to RMB 963.92 million in 2023 compared to RMB 1.82 billion in 2022[90] - Bicycle parts revenue dropped by 55.47% to RMB 666.58 million, accounting for 69.15% of total revenue[90] - Sports and fitness rehabilitation equipment revenue decreased by 9.02% to RMB 283.47 million, making up 29.41% of total revenue[90] - Domestic sales accounted for 42.06% of total revenue, decreasing by 37.81% to RMB 405.39 million[90] Production and Sales Volume Decline - Bicycle parts sales volume fell by 54.47% to 2.01 million units, with production volume dropping by 58.82% to 1.78 million units[93] - Sports and fitness rehabilitation equipment sales volume decreased by 11.07% to 208,100 units, with production volume down by 5.98% to 195,100 units[93] Customer and Supplier Concentration - Top five customers contributed 35.15% of total sales, with the largest customer accounting for 16.54% of total revenue[99][100] - Top five suppliers accounted for 16.03% of total procurement, with the largest supplier contributing 3.61%[100] Subsidiary Establishment and R&D - The company established a new subsidiary, Shenzhen Laiqi Technology Co., Ltd., in October 2023 with a registered capital of RMB 10 million[98] - R&D expenses decreased by 19.44% to RMB 45.58 million in 2023 compared to RMB 56.58 million in 2022[102][104] - R&D personnel decreased by 13.25% to 406 in 2023 from 468 in 2022, with a slight increase in R&D personnel ratio to 16.76%[103] Cash Flow and Financial Activities - Operating cash flow decreased by 25.59% to RMB 274.81 million in 2023 from RMB 369.32 million in 2022[105] - Investment cash inflow surged by 2311.38% to RMB 58.79 million in 2023 due to the recovery of structured deposits[106] - Investment cash outflow increased by 112.83% to RMB 170.11 million in 2023, mainly due to increased cash expenditures on fixed assets[106] - Net cash flow from financing activities improved by 33.86% to a negative RMB 172.31 million in 2023[106] Profit and Non-Operating Income - Net profit was RMB 18.34 million, significantly lower than the operating cash flow of RMB 276.22 million, mainly due to reduced inventory and lower depreciation expenses[107] - Non-operating income reached RMB 24.15 million, accounting for 172.78% of total profit, primarily from temporary relocation fees[109] - Asset impairment losses amounted to RMB 6.49 million, accounting for 46.42% of total profit, mainly due to inventory obsolescence and idle fixed assets[109] - Government subsidies contributed RMB 1.60 million, accounting for 11.43% of total profit[109] Strategic Goals and Market Expansion - Revenue growth is the primary goal, with a focus on new product development and new customer acquisition[155] - Actively visiting overseas customers to develop new business opportunities[155] - Participating in domestic medical exhibitions to expand the domestic market[155] - Investing in the development of manual and electric wheelchair ODM products[155] - Developing proprietary ODM products, such as electric wheelchairs with lifting mechanisms[155] - Establishing a cost reduction project to meet customer pricing requirements[155] - Optimizing business and operational management processes to prepare for future growth[155] Export Sales and Tariff Impact - Direct export sales accounted for 64.28% of total sales in 2022[156] - Bicycle parts exports are indirectly affected by US tariffs but not by EU anti-dumping duties[156] Corporate Governance and Independence - The company has established a comprehensive internal audit system, with an internal audit institution reporting directly to the Board Audit Committee, ensuring independence and effectiveness in auditing internal controls and financial activities[170] - The company maintains complete independence in assets, personnel, finance, organization, and business operations, with no reliance on shareholders for production or business premises[172] - The company's personnel, including directors, supervisors, and senior management, are independently appointed and remunerated, with no overlap in roles with shareholders or related enterprises[173] - The company has an independent financial department established since 1991, adhering to the "Enterprise Accounting Standards" and maintaining separate bank accounts and tax filings[174] - The company operates independently in its core business of bicycle parts and sports fitness rehabilitation equipment, with no overlap in business activities with shareholders or related enterprises[175] Shareholder Meetings and Resolutions - The 2022 Annual General Meeting had a 51.17% investor participation rate, with key resolutions including the approval of the 2022 financial report and profit distribution plan[176] Executive Compensation - The company strictly adheres to the "Compensation System for Directors, Supervisors, and Senior Management," with actual compensation for 2023 approved by the Remuneration and Assessment Committee and disclosed in the 2023 annual report[199] - Each director/supervisor receives an annual remuneration of 120,000 RMB (after tax deduction), paid monthly, with taxes withheld by the company[199] - The remuneration for directors and supervisors was revised and approved at the 2022 first extraordinary general meeting, effective from May 2022[199]

证券代码：002105 证券简称：信隆健康 公告编号：2024-012 深圳信隆健康产业发展股份有限公司 关于举行2023年年度报告网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司（以下简称：公司）将于2024年5月17日（星期五）下午 15:00-17:00 在全景网"投资者关系互动平台"举行2023年年度报告网上说明会，本次说明会将 采用网络远程方式举行，投资者可登陆投资者互动平台：http://irm.p5w.net 参与本次说明会。 公司出席本次说明会的人员有：公司董事长廖学金先生、董事会秘书陈丽秋女士、财务总监 邱东华先生、独立董事高海军先生。 欢迎广大投资者积极参与！ 特此公告。 深圳信隆健康产业发展股份有限公司董事会 2024年4月24日 ...

2024 年 4 月 22 日 董事会关于独立董事独立性自查情况的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等要求， 深圳信隆健康产业发展股份有限公司（以下简称"公司"）董事会，就公司在任独立董事高 海军先生、陈大路先生、王巍望女士、甘勇明先生的独立性情况进行评估并出具如下专项意 见： 经核查独立董事高海军先生、陈大路先生、王巍望女士、甘勇明先生的任职经历以及签 署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股 东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立 客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》中对独立董事 独立性的相关要求。 深圳信隆健康产业发展股份有限公司 董事会 深圳信隆健康产业发展股份有限公司 ...